遥望科技(002291)FY22&1Q23业绩交流会-调研纪要.pdf

Mandi led growth in FY22E, NRDL renewal de-risked

华润医药：1H22业绩巩固了FY22E的正面

石四药集团：强劲的1H22结果；但FY22E指引略低

知乎（ZH US）4Q21E 稳健，FY22E 过渡

Resilient FY22／1H23 despite industry headwinds

思摩尔国际(06969)FY22 业绩会纪要-港股-调研纪要

IMAX China(01970)FY22业绩会纪要-港股20230223-调研纪要

FY22 net margins better than expected

FY22销售成绩优异，核心产品加速渗透目标市场

FY22 Preview： Strong execution of “3+3 Strategy”; Raise TP to HK$2.66